|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1999-3-29
|
|
pubmed:abstractText |
The authors designed this randomized, controlled trial to assess whether dose intensification of a cisplatin-etoposide combination (PE), achieved by shortening the interval between chemotherapy cycles, would improve response rate and survival. The maximum tolerated dose of PE was administered in either 3- or 4-week cycles to patients with advanced nonsmall cell lung carcinoma (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
855-63
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10091762-Adult,
pubmed-meshheading:10091762-Aged,
pubmed-meshheading:10091762-Agranulocytosis,
pubmed-meshheading:10091762-Analysis of Variance,
pubmed-meshheading:10091762-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10091762-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10091762-Cisplatin,
pubmed-meshheading:10091762-Dose-Response Relationship, Drug,
pubmed-meshheading:10091762-Drug Administration Schedule,
pubmed-meshheading:10091762-Etoposide,
pubmed-meshheading:10091762-Female,
pubmed-meshheading:10091762-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:10091762-Humans,
pubmed-meshheading:10091762-Lung Neoplasms,
pubmed-meshheading:10091762-Male,
pubmed-meshheading:10091762-Middle Aged,
pubmed-meshheading:10091762-Neoplasm Staging,
pubmed-meshheading:10091762-Neutropenia,
pubmed-meshheading:10091762-Survival Analysis,
pubmed-meshheading:10091762-Thrombocytopenia,
pubmed-meshheading:10091762-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
|
|
pubmed:affiliation |
Medical Oncology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
